Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 2;9(4):742.
doi: 10.3390/microorganisms9040742.

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

Maria Deloria Knoll  1 , Julia C Bennett  1 , Maria Garcia Quesada  1 , Eunice W Kagucia  2 , Meagan E Peterson  1 , Daniel R Feikin  3 , Adam L Cohen  4 , Marissa K Hetrich  1 , Yangyupei Yang  1 , Jenna N Sinkevitch  1 , Krow Ampofo  5 , Laurie Aukes  6 , Sabrina Bacci  7 , Godfrey Bigogo  8 , Maria-Cristina C Brandileone  9 , Michael G Bruce  10 , Romina Camilli  11 , Jesús Castilla  12   13 , Guanhao Chan  14 , Grettel Chanto Chacón  15 , Pilar Ciruela  12   16 , Heather Cook  17 , Mary Corcoran  18 , Ron Dagan  19 , Kostas Danis  20 , Sara de Miguel  21 , Philippe De Wals  22 , Stefanie Desmet  23   24 , Yvonne Galloway  25 , Theano Georgakopoulou  26 , Laura L Hammitt  1   2 , Markus Hilty  27 , Pak-Leung Ho  28 , Sanjay Jayasinghe  29 , James D Kellner  30 , Jackie Kleynhans  31   32 , Mirjam J Knol  33 , Jana Kozakova  34 , Karl Gústaf Kristinsson  35 , Shamez N Ladhani  36 , Claudia S Lara  37 , Maria Eugenia León  38 , Tiia Lepp  39 , Grant A Mackenzie  40   41   42 , Lucia Mad'arová  43 , Allison McGeer  44 , Tuya Mungun  45 , Jason M Mwenda  46 , J Pekka Nuorti  47   48 , Néhémie Nzoyikorera  49   50 , Kazunori Oishi  51 , Lucia Helena De Oliveira  52 , Metka Paragi  53 , Tamara Pilishvili  54 , Rodrigo Puentes  55 , Eric Rafai  56 , Samir K Saha  57 , Larisa Savrasova  58   59 , Camelia Savulescu  60 , J Anthony Scott  2 , Kevin J Scott  61 , Fatima Serhan  4 , Lena Petrova Setchanova  62 , Nadja Sinkovec Zorko  63 , Anna Skoczyńska  64 , Todd D Swarthout  65   66 , Palle Valentiner-Branth  67 , Mark van der Linden  68 , Didrik F Vestrheim  69 , Anne von Gottberg  31   70 , Inci Yildirim  71 , Kyla Hayford  1 ; The Pserenade Team
Collaborators, Affiliations

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

Maria Deloria Knoll et al. Microorganisms. .

Abstract

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.

Keywords: global; invasive pneumococcal disease; pneumococcal conjugate vaccines; pneumococcal meningitis; surveillance.

PubMed Disclaimer

Conflict of interest statement

KH conducted the study and analyses while working at the Johns Hopkins School of Public Health but is an employee at Pfizer, Inc. as of 26 October 2020. JCB reports funding from Pfizer in the past year, unrelated to the submitted work. MDK reports grants from Merck, personal fees from Merck, and grants from Pfizer, outside the submitted work. JAS reports grants from the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK MRC, National Institute of Health Research, outside the submitted work. MCB reports lectures fee from MSD outside from submitted work. AS reports grants and personal fees from Pfizer and personal fees from MSD and Sanofi Pasteur, outside the submitted work. ML has been a member of advisory boards and has received speakers’ honoraria from Pfizer and Merck. German pneumococcal surveillance has been supported by Pfizer and Merck. SD reports grant from Pfizer, outside the submitted work. KA reports a grant from Merck, outside the submitted work. MC has previously received a professional fee from Pfizer (Ireland), an unrestricted research grant from Pfizer Ireland (2007–2016) and an Investigator Initiated Reward from Pfizer Ireland in 2018 (W1243730). AvG has received researching funding from Pfizer (last year 2017, Pfizer Investigator-Initiated Research [IIR] Program IIR WI 194379); attended advisory board meetings for Pfizer and Merck. AM received research support to her institution from Pfizer and Merck; honoraria for advisory board membership from GlaxoSmithKline, Merck and Pfizer. SNL performs contract research for GSK, Pfizer, Sanofi Pasteur on behalf of St. George’s University of London, but receives no personal remuneration. IY stated she was a member of mRNA-1273 study group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron. RD has received grants/research support from Pfizer, Merck Sharp & Dohme and Medimmune; has been a scientific consultant for Pfizer, MeMed, Merck Sharp & Dohme, and Biondvax; had served on advisory boards of Pfizer, Merck Sharp & Dohme and Biondvax and has been a speaker for Pfizer. MH received an educational grant from Pfizer AG for partial support of this project. However, Pfizer AG had no role in the data analysis and content of the manuscript. CLB, MD has intellectual property in BioFire Diagnostics and receives royalties through the University of Utah. CLB is an advisor to IDbyDNA. AK reports personal fees from Pfizer, outside the submitted work. MT reports grants from GlaxoSmithKline and grants from Pfizer Inc. to the Finnish Institute for Health and Welfare for research projects outside the submitted work, in which she has been a co-investigator. JCS reports had received assistance from Pfizer for attending scientific meetings outside the submitted work. NPK has received research support from Pfizer for studies on pneumococcal serotyping and pneumococcal conjugate vaccine effectiveness. NPK has also received research support for unrelated studies from GlaxoSmithKline, Sanofi Pasteur, Merck, and Protein Sciences (now Sanofi Pasteur). SCGA received a travel grant from Pfizer. CMA reports grants and personal fees from Pfizer, Qiagen, and BioMerieux and grants from Genomica SAU, outside the submitted work. BL had two research grants from Pfizer on Streptococcus pneumoniae. EV reports grants from the French public health agency, during the conduct of the study; grants from Pfizer, grants from Merck, outside the submitted work. LLH reports research grants to her institution from GSK, Pfizer, and Merck. JDK has received an unrestricted grant-in-aid from Pfizer Canada that supports, in part, the CASPER invasive pneumococcal disease surveillance project. CGS reports grant funding from Pfizer, Merck, and AstraZeneca in the past three years. NMvS reports grants and fee for service from Pfizer, fee for service from MSD and GSK, outside the submitted work; In addition, NMvS has a patent WO 2013/020090 A3 with royalties paid to University of California San Diego (inventors: Nina van Sorge/Victor Nizet). All other authors did not declare any conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Availability of IPD surveillance data for countries with universal recommendations for PCV in the infant immunization program. 1 Cases from multiple surveillance sites within the same country were aggregated.2 PCV not universally introduced into the routine infant immunization program by 2018 (includes India which began sub-national introduction in 2017). 3 IPD surveillance data did not meet PSERENADE data collection eligibility criteria (Box 1). 4 IPD surveillance data met data collection eligibility criteria but did not participate in PSERENADE.
See this image and copyright information in PMC

References

    1. Wahl B., O’Brien K.L., Greenbaum A., Majumder A., Liu L., Chu Y., Lukšić I., Nair H., McAllister D.A., Campbell H., et al. Burden of Streptococcus Pneumoniae and Haemophilus Influenzae Type b Disease in Children in the Era of Conjugate Vaccines: Global, Regional, and National Estimates for 2000–15. Lancet Glob. Health. 2018;6:e744–e757. doi: 10.1016/S2214-109X(18)30247-X. - DOI - PMC - PubMed
    1. World Health Organization Pneumococcal Disease. [(accessed on 4 January 2021)]; Available online: https://www.who.int/ith/diseases/pneumococcal/en/
    1. World Health Organization Pneumococcal Conjugate Vaccine for Childhood Immunization—WHO Position Paper. Wkly. Epidemiol. Rec. 2007;82:93–104. - PubMed
    1. World Health Organization Pneumococcal Conjugate Vaccines in Infants and Children under 5 Years of Age: WHO Position Paper. Wkly. Epidemiol. Rec. 2019;94:85–104.
    1. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health VIEW-Hub. [(accessed on 29 December 2020)]; Available online: https://view-hub.org.